Candidate: Vaccine against CoVID-19

Category: VAX

Type: Live-attenuated vaccine

Status: Codagenix said February 13 it will collaborate with the Serum Institute of India to rapidly co-develop a COVID-19 vaccine, adding that it has already designed “multiple” novel coronavirus vaccine candidate genomes using its proprietary deoptimization technology, which can digitally generate a full-length, deoptimized genome based on the outbreak sequence 3–5 days after acquiring the sequence.

Vaccine viruses will be grown and tested in vivo by contracted laboratories suitable for containment, before testing in clinical trials. The Serum Institute of India, a vaccine manufacturer and distributor with a global presence, will scale-up the manufacture of the vaccine to ensure its availability. Codagenix and Serum Institute said they are pursuing an accelerated development pathway and were eager to manufacture and test their vaccine candidates “as quickly as possible.”


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA